Sonnet BioTherapeutics (SONN) Competitors $3.47 +0.09 (+2.66%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.50 +0.03 (+0.98%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. CLNN, RENB, XCUR, SLGL, PEPG, SNTI, HYPD, EGRX, CALC, and LVTXShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Clene (CLNN), Renovaro (RENB), Exicure (XCUR), Sol-Gel Technologies (SLGL), PepGen (PEPG), Senti Biosciences (SNTI), Hyperion DeFi (HYPD), Eagle Pharmaceuticals (EGRX), CalciMedica (CALC), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors Clene Renovaro Exicure Sol-Gel Technologies PepGen Senti Biosciences Hyperion DeFi Eagle Pharmaceuticals CalciMedica LAVA Therapeutics Sonnet BioTherapeutics (NASDAQ:SONN) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Is SONN or CLNN more profitable? Sonnet BioTherapeutics has a net margin of 0.00% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -4,646.10% -342.21% Clene -10,386.36%N/A -125.49% Do analysts prefer SONN or CLNN? Sonnet BioTherapeutics presently has a consensus price target of $20.00, indicating a potential upside of 476.37%. Clene has a consensus price target of $33.00, indicating a potential upside of 483.04%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Sonnet BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders & institutionals believe in SONN or CLNN? 9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by company insiders. Comparatively, 35.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger earnings & valuation, SONN or CLNN? Sonnet BioTherapeutics has higher earnings, but lower revenue than Clene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$20K1,171.13-$7.44MN/AN/AClene$340K166.30-$39.40M-$3.76-1.51 Which has more volatility & risk, SONN or CLNN? Sonnet BioTherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Does the media favor SONN or CLNN? In the previous week, Clene had 11 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 12 mentions for Clene and 1 mentions for Sonnet BioTherapeutics. Sonnet BioTherapeutics' average media sentiment score of 0.00 beat Clene's score of -0.24 indicating that Sonnet BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonnet BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Clene 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryClene beats Sonnet BioTherapeutics on 10 of the 15 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.44M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E RatioN/A21.0031.3026.05Price / Sales1,171.13357.30455.25117.77Price / CashN/A44.5038.0259.36Price / Book-7.718.129.536.60Net Income-$7.44M-$54.72M$3.26B$265.65M7 Day Performance-1.98%2.62%2.14%2.01%1 Month Performance-24.07%2.68%2.81%-0.33%1 Year Performance-42.17%10.93%30.70%19.04% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.5668 of 5 stars$3.47+2.7%$20.00+476.4%-38.1%$23.44M$20K0.0010Gap DownCLNNClene3.2398 of 5 stars$4.33+2.0%$33.00+662.8%+6.8%$43.31M$340K-1.15100Analyst ForecastRENBRenovaroN/A$0.25+5.9%N/A-63.7%$43.03MN/A-0.3220XCURExicure1.8927 of 5 stars$6.78+3.5%N/A+1,455.6%$42.85M$500K-1.7550Gap UpSLGLSol-Gel Technologies0.7994 of 5 stars$16.01+3.7%N/A+226.2%$42.76M$23.93M-12.4850News CoverageEarnings ReportGap DownPEPGPepGen3.2303 of 5 stars$1.32+2.3%$7.67+480.8%-86.4%$42.64MN/A-0.4430SNTISenti Biosciences2.5753 of 5 stars$1.63+1.6%$8.50+423.1%-38.6%$42.51M$2.56M-0.184HYPDHyperion DeFi0.3639 of 5 stars$7.31-2.0%$2.00-72.6%-85.9%$41.59M$60K-0.1340Gap DownEGRXEagle Pharmaceuticals1.7514 of 5 stars$3.20flatN/AN/A$41.56M$257.55M0.00100Gap DownCALCCalciMedica3.4519 of 5 stars$2.90-1.3%$16.00+451.3%-33.5%$40.67MN/A-1.8230LVTXLAVA Therapeutics1.5253 of 5 stars$1.53+0.3%$2.69+76.1%-18.2%$40.25M$11.98M-1.4660Short Interest ↓ Related Companies and Tools Related Companies Clene Competitors Renovaro Competitors Exicure Competitors Sol-Gel Technologies Competitors PepGen Competitors Senti Biosciences Competitors Hyperion DeFi Competitors Eagle Pharmaceuticals Competitors CalciMedica Competitors LAVA Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access